Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice

Blood

Volumn 109, Issue 2, 2007, Pages 811-818

  Lyoumi, Saïd ^a,b   Abitbol, Marie ^c,d   Andrieu, Valérie ^e   Henin, Dominique ^f   Robert, Elodie ^a   Schmitt, Caroline ^a,b   Gouya, Laurent ^a,b   De Verneuil, Hubert ^a   Deybach, Jean Charles ^a,b   Montagutelli, Xavier ^c,d   Beaumont, Carole ^a,b,g   Puy, Hervé ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Laboratoire d'Hématologie   (France)

^f Laboratoire d'Anatomo pathologie   (France)

^g CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE PROTOPORPHYRIN; FERROCHELATASE; HEPCIDIN; IRON; MESSENGER RNA; PROTOPORPHYRIN; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY DISTRIBUTION; BONE MARROW CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ERYTHROID CELL; FEMALE; INTESTINE CELL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSFERRIN BLOOD LEVEL;

EID: 33846256111     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-014142     Document Type: Article

References (50)

1. Sassa S, Kappas A. Molecular aspects of the inherited porphyrias. J Intern Med. 2000;247:169-178.
2. Cox TM. Erythropoietic protoporphyria. J Inherit Metab Dis. 1997;20:258-269.
3. Bloomer J, Wang Y, Singhal A, Risheg H. Molecular studies of liver disease in erythropoietic protoporphyria. J Clin Gastroenterol. 2005;39:S167-S175.
4. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wild-type FECH. Nat Genet. 2002;30:27-28.
5. Gouya L, Martin-Schmitt C, Robreau AM, et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet. 2006;78:2-14.
6. Brun A, Sandberg S. Mechanisms of photosensitivity in porphyric patients with special emphasis on erythropoietic protoporphyria. J Photochem Photobiol B. 1991;10:285-302.
7. Meerman L. Erythropoietic protoporphyria: an overview with emphasis on the liver. Scand J Gastroenterol Suppl. 2000:79-85.
8. Schneider-Yin X, Gouya L, Meier-Weinand A, Deybach JC, Minder EI. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr. 2000;159:719-725.
9. Todd DJ. Erythropoietic protoporphyria. Br J Dermatol. 1994;131:751-766.
10. Nakahashi Y, Miyazaki H, Kadota Y, et al. Molecular defect in human erythropoietic protoporphyria with fatal liver failure. Hum Genet. 1993;91:303-306.
11. Baart de la Faille H, Bijlmer-Iest JC, van Hattum J, Koningsberger J, Rademakers LH, van Welden H. Erythropoietic protoporphyria: clinical aspects with emphasis on the skin [review]. Curr Problems Dermatol. 1991;20:123-134.
12. DeLeo VA, Poh-Fitzpatrick M, Mathews-Roth M, Harber LC. Erythropoietic protoporphyria: 10 years experience. Am J Med. 1976;60:8-22.
13. Magness ST, Maeda N, Brenner DA. An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria. Blood. 2002;100:1470-1477.
14. Tutois S, Montagutelli X, Da Silva V, et al. Erythropoietic protoporphyria in the house mouse: a recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease. J Clin Invest. 1991;88:1730-1736.
15. Boulechfar S, Lamoril J, Montagutelli X, et al. Ferrochelatase structural mutant (Fechm1Pas) in the house mouse. Genomics. 1993;16:645-648.
16. Richard E, Robert E, Cario-Andre M, et al. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection. Gene Ther. 2004;11:1638-1647.
17. Abitbol M, Bernex F, Puy H, et al. A mouse model provides evidence that genetic background modulates anemia and liver injury in erythropoietic protoporphyria. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1208-G1216.
18. Poulos V, Lockwood WH. A rapid method for estimating red blood cell porphyrin. Int J Biochem. 1980;12:1049-1050.
19. Li FM, Lim CK, Peters TJ. An HPLC assay for rat liver ferrochelatase activity. Biomed Chromatogr. 1987;2:164-168.
20. Martin ME, Nicolas G, Hetet G, Vaulont S, Grandchamp B, Beaumont C. Transferrin receptor 1 mRNA is downregulated in placenta of hepcidin transgenic embryos. FEBS Lett. 2004;574:187-191.
21. Marsden CH, Simmonds RG. Purification of mouse haptoglobin by antibody affinity chromatography and development of an ELISA to measure serum haptoglobin levels. J Immunol Methods. 1988;108:53-59.
22. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinised liver samples. S Afr J Med Sci. 1968;33:9-11.
23. Simpson RJ, Peters TJ. Studies of Fe3+ transport across isolated intestinal brush-border membrane of the mouse. Biochim Biophys Acta. 1984;772:220-226.
24. Pountney DJ, Raja KB, Simpson RJ, Wrigglesworth JM. The ferric-reducing activity of duodenal brush-border membrane vesicles is associated with a b-type haem. Biometals. 1999;12:53-62.
25. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001;98:8780-8785.
26. Moreau-Gaudry F, Xia P, Jiang G, et al. High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood. 2001;98:2664-2672.
27. van Krieken JH, te Velde J, Hermans J, Cornelisse CJ, Welvaart C, Ferrari M. The amount of white pulp in the spleen; a morphometrical study done in methacrylate-embedded splenectomy specimens. Histopathology. 1983;7:767-782.
28. Ganz T, Nemeth E. Iron imports, IV: hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006;290:G199-G203.
29. McKie AT, Barrow D, Latunde-Dada GO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 2001;291:1755-1759.
30. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol. 2005;18:319-332.
31. Beamer WG, Pelsue SC, Shultz LD, Sundberg JP, Barker JE. The flaky skin (fsn) mutation in mice: map location and description of the anemia. Blood. 1995;86:3220-3226.
32. R'Zik S, Loo M, Beguin Y. Reticulocyte transferrin receptor (TfR) expression and contribution to soluble TfR levels. Haematologica. 2001;86:244-251.
33. Bloomer JR, Hill HD, Kools AM, Straka JG. Heme synthesis in protoporphyria. Curr Problems Dermatol. 1991;20:135-147.
34. Brun A, Steen H, Sandberg S. Erythropoietic protoporphyria: two populations of reticulocytes, with and without protoporphyrin. Eur J Clin Invest. 1996;26:270-278.
35. Mathews-Roth MM. Anemia in erythropoietic protoporphyria [letter]. JAMA. 1974;230:824.
36. Rothstein G, Lee R, Cartwright GE. Sideroblastic anemia with dermal photosensitivity and greatly increased erythrocyte protoporphyrin. N Engl J Med. 1969;280:587-590.
37. Romslo I, Brun A, Sandberg S, Bottomley SS, Hovding G, Talstad I. Sideroblastic anemia with markedly increased free erythrocyte protoporphyrin without dermal photosensitivity. Blood. 1982;59:628-633.
38. Lim HW, Cooper D, Sassa S, Dosik H, Buchness MR, Soter NA. Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia. J Am Acad Dermatol. 1992;27:287-292.
39. Rademakers LH, Koningsberger JC, Sorber CW, Baart de la Faille H, Van Hattum J, Marx JJ. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest. 1993;23:130-138.
40. Aplin C, Whatley SD, Thompson P, et al. Late-onset erythropoietic porphyria caused by a chromosome 18q deletion in erythroid cells. J Invest Dermatol. 2001;117:1647-1649.
41. Turnbull A, Baker H, Vernon-Roberts B, Magnus IA. Iron metabolism in porphyria cutanea tarda and in erythropoietic protoporphyria. Q J Med. 1973;42:341-355.
42. Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol. 2004;124:123-124.
43. Frazer DM, Anderson GJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol Dis. 2003;30:288-297.
44. Fitzsimons EJ, May A. The molecular basis of the sideroblastic anemias. Curr Opin Hematol. 1996;3:167-172.
45. Nakajima O, Okano S, Harada H, et al. Transgenic rescue of erythroid 5-aminolevulinate synthase-deficient mice results in the formation of ring sideroblasts and siderocytes. Genes Cells. 2006;11:685-700.
46. Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood. 2000;96:3256-3264.
47. Li J, Kogan M, Knight SA, Pain D, Dancis A. Yeast mitochondrial protein, Nfs1p, coordinately regulates iron-sulfur cluster proteins, cellular iron uptake, and iron distribution. J Biol Chem. 1999;274:33025-33034.
48. Hentze MW, Kuhn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A. 1996;93:8175-8182.
49. Schranzhofer M, Schifrer M, Cabrera JA, et al. Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis. Blood. 2006;107:4159-4167.
50. Milligan A, Graham-Brown RA, Sarkany I, Baker H. Erythropoietic protoporphyria exacerbated by oral iron therapy. Br J Dermatol. 1988;119:63-66.